



Cyclacel Pharmaceuticals, Inc.
 Investor Relations Department
 200 Connell Drive, Suite 1500
 Berkeley Heights, NJ 07922
 United States

[Visit IR website](#)

[Sign-up for email alerts](#)

NASDAQ: CYCC ¹

Last Trade:	4.09
Trade Time:	3:59 PM ET Jun 28, 2017
Change:	0.00 (0.000%)
Day Range	N/A - N/A
52-Week Range	3.05 - 10.90
Volume	N/A
Market Cap. (\$M)	18.160
Shares Out (M)	4.440

¹ The stock information is provided by eSignal, stock charts are provided by EDGAR Online. Stock information is delayed approximately 20 minutes.

Company Profile

We are a development-stage biopharmaceutical company dedicated to the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a portfolio of commercial products and a development pipeline of novel drug candidates.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 11, 2017
[Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results](#)
- May 5, 2017
[Cyclacel Pharmaceuticals to Release First Quarter 2017 Financial Results](#)
- Apr 4, 2017
[Cyclacel Presents Identification of Sensitive Target Indications and Synergistic Drug Combinations for Novel PLK1 Inhibitor CYC140](#)
- Apr 2, 2017
[Cyclacel's Second-Generation CDK2/9 Inhibitor, CYC065, Elicits Marked Antineoplastic Effects in Lung Cancer by Engaging Anti-Metastatic Pathways](#)
- Mar 28, 2017
[Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results](#)

Events [\[View all \]](#)

There are no events to display at this time. Please check back later.

Financials [\[View all \]](#)

- Mar 31, 2017
[Annual Report \(10-K\)](#)
- Apr 12, 2017
[Definitive Proxy Statement](#)
- May 12, 2017
[Quarterly Report \(10-Q\)](#)
- Nov 14, 2016
[Quarterly Report \(10-Q\)](#)
- Aug 11, 2016
[Quarterly Report \(10-Q\)](#)